ADDRESSING THE MAJOR CHALLENGES IN HIV VACCINE AND CURE RESEARCH
Grant number: 1149990 | Funding period: 2019 - 2023
HIV remains one of the defining global health challenge of our times. 37 million people are living with HIV with 2 million new infections each year. Despite advances in management of HIV infection with antiretroviral therapy, there is still no cure, no effective vaccine, and several co-infections reduce life expectancy. This program assembles Australia’s leading HIV researchers to use innovative basic and translational science to tackle priority areas in controlling the HIV epidemic.
Related publications (4)
Suboptimal SARS-CoV-2-specific CD8( ) T cell response associated with the prominent HLA-A*02:01 phenotype
Jennifer R Habel, Thi HO Nguyen, Carolien E van de Sandt, Jennifer A Juno, Priyanka Chaurasia, Kathleen Wragg, Marios Koutsakos, Luca Hensen, Xiaoxiao Jia, Brendon Chua, Wuji Zhang, Hyon-Xhi Tan, Katie L Flanagan, Denise L Doolan, Joseph Torresi, Weisan Chen, Linda M Wakim, Allen C Cheng, Peter C Doherty, Jan Petersen
An improved understanding of human T cell-mediated immunity in COVID-19 is important for optimizing therapeutic and vaccine strate..
Template-Mediated Assembly of DNA into Microcapsules for Immunological Modulation
Yijiao Qu, Yi Ju, Christina Cortez-Jugo, Zhixing Lin, Shiyao Li, Jiajing Zhou, Yutian Ma, Agata Glab, Stephen J Kent, Francesca Cavalieri, Frank Caruso
There is a need for effective vaccine delivery systems and vaccine adjuvants without extraneous excipients that can compromise or ..
Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation.
Hannah G Kelly, Hyon-Xhi Tan, Jennifer A Juno, Robyn Esterbauer, Yi Ju, Wenbo Jiang, Verena C Wimmer, Brigette C Duckworth, Joanna R Groom, Frank Caruso, Masaru Kanekiyo, Stephen J Kent, Adam K Wheatley
Protein-based, self-assembling nanoparticles elicit superior immunity compared with soluble protein vaccines, but the immune mecha..